You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Business Description: Resmed Inc. (RMD) is a global company involved in the development, manufacturing and marketing of innovative medical products for the treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. RMD sells a broad range of products in more than 70 countries worldwide through direct offices and a network of distributors.
Strategy Analysis: RMD develops medical devices to treat patients with breathing disorders. It focuses primarily on sleep apnea and aims to educate the public and physicians about the negative effects of this problem. The firm continually upgrades its devices to improve patient experiences. RMD uses acquisitions to fill out its distribution network and product set.
ResMed Inc. reported NPAT up 19% to US$226.99m for the year ended 30 June 2011. Revenues from ordinary activities were US$1.24bn, up 14% from last year. The increase in net revenue was attributable to an increase in unit sales of the Company's flow generators, masks and accessories. Diluted EPS was 1.44 cents compared to 1.23 cents last year. Net operating cash flow was $283.19m compared to $188.21m last year. No dividend was declared.
The Age 19/06/2013 |
The bullish sentiments on the sharemarket earlier this year have been challenged by a correction that has taken the All Ordinaries Index down about 10 per cent from its May highs. Many investors are now asking how deep the current correction is likely to be.
The Age 19/06/2013 |
Done well, value investing is a successful, safe way to invest. The logic of the approach - buying an asset for less than its underlying value - is irrefutable.
The Age 19/06/2013 |
Snowballing debts and no means to repay them ... going bankrupt is the last-ditch option for those in a financial hole too deep to climb out from.
The Age 19/06/2013 |
One of the weapons an individual has over institutions is time, and with real value emerging at the micro-cap end of the market, smaller stocks are an area worth holding on to.
The Age 19/06/2013 |
Spending 10 days in Japan gives one a good overview of what they call "Abenomics" and its impact, and that includes also being here for one of the biggest drops on the Japanese market in weeks.
The Age 19/06/2013 |
Lend Lease has moved to allay investors' concerns with the issue of a formal profit guidance of between $540 million and $550 million for the full year, despite the weakness in the construction sector.
Already a member? 
$ 5.060
